Chemotherapy-induced apoptosis in melanoma cells is p53 dependent

Melanoma Research

Volumn 8, Issue 1, 1998, Pages 17-23

  Li, G ^a,b   Tang, L ^a   Zhou, X ^a   Tron, V ^a   Ho, V ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

Apoptosis; Chemotherapy; Melanoma; P53

Indexed keywords

ALKYLATING AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; PROTEIN P53; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL DIVISION; CELL SURVIVAL; CISPLATIN; DNA FRAGMENTATION; DNA, NEOPLASM; ELECTROPHORESIS, AGAR GEL; GENES, P53; HUMANS; MELANOCYTES; MELANOMA; MUTATION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0031942550     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199802000-00004     Document Type: Article

References (41)

1. Li G, Ho VC, Trotter MJ, Horsman DE, Tron VA. p53 mutation in metastatic melanomas and primary melanomas from sun-exposed and sun-protected sites. J Eur Acad Dermatol Venereal 1995; 4: 48-53.
2. Lassam LA, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53: 2235-2238.
3. Cristofolini M, Boi S, Girlando S, Zumiani G, Cristofolini P, Dalla Palma P, Doglioni C, Barbareschi M. p53 protein expression in nevi and melanomas. Arch Dermatol 1993; 129: 739-743.
4. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995; 5: 93-100.
5. Weiss J, Heine M, Arden KC, Korner B, Pilch H, Herbst RA, Jung EG. Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res 1995; 139: 137-154.
6. Albino AP, Widal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994; 4: 35-45.
7. Hartmann A, Blaszyk H, Cunnigham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS. Overexpression and mutations of p53 in metastatic melanomas, Int J Cancer 1996; 67: 313-317.
8. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment of a programmed cell death? Br J Cancer 1991; 64: 192-196.
9. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995; 55: 2122-2128.
10. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353-2362.
11. Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 1991; 51: 6280-6285.
12. Evan DL, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 1993; 53: 2133-2139.
13. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991; 24: 203-214.
14. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989; 49: 5870-5878.
15. Candi E, Melino G, De Laurenzi V, Piacentini M, Guerrieri P, Spinedi A, Knight RA. Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 1995; 96: 141-145.
16. Mohammad RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B, al-Katib A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leukemia Res 1995; 19: 667-673.
17. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC Jr. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Am J Pathol 1991; 139: 423-435.
18. Bae I, Smith ML, Sheikh S, Zhan Q, Scudiero DA, Friend SH, O'Connor PM, Fornace AJ Jr. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines. Cancer Res 1993; 53: 2235-2238.
19. Vidal MJ, Loganzo F Jr, de Oliveira AR, Hayward NK, Albino AP Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res 1995; 5: 243-250.
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica C, Warren JT, Bokesch H, Kenny S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
21. Nabeya Y, Loganzo F Jr, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995; 64: 37-46.
22. Moll UM, Ostermeyer AG, Ahomadegbe JC, Mathieu MC, Riou G. p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum Pathol 1995; 26: 1293-1301.
23. Lowe SW Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
24. Zhang N, Song Q, Lu H, Lavin ME Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells. Oncogene 1996; 13: 655-659.
25. waf1/ciP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinogenesis 1996; 16: 20-31.
26. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
27. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993; 75: 765-778.
28. Li G, Mitchell DL, Ho VC, Reed JC, Tron VA. Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. Am J Pathol 1996; 148: 1113-1123
29. Li G, Ho VC, Mitchell DL, Trotter MJ, Tron VA. Differentiation-dependent p53 regulation of nucleotide excision repair in keratinocytes. Am J Pathol 1997; 150: 1457-1464.
30. O'Neill CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walsweer Y, Kelland LR. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(TV) complex. Br J Cancer 1996; 74: 1037-1045.
31. Samuel LM, Harvey VJ, Mitchelol PL, Thompson PI, Mak D, Melville P, Evans BD. Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. EurJ Cancer 1994; 30: 2054-2056.
32. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 1993; 4: 291-299.
33. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995; 146: 643-650.
34. Hawkins DS, Demers W, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 892-898.
35. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993; 53: 4776-4780.
36. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824-5830.
37. Righetti SC, Torre GD, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F. A comparative study of p53 gene mutation, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-693.
38. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
39. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993; 53: 3667-3669.
40. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinogenesis 1995; 14: 275-285.
41. Cirielli C, Riccioni T, Yang C, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC. Adenovirusmediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer 1995; 63: 673-679.